In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Abstract Combined Annotation-Dependent Depletion (CADD) is a widely used measure of
variant deleteriousness that can effectively prioritize causal variants in genetic analyses …

Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …

Abstract Purpose of Review Early-onset Alzheimer's disease (EOAD), defined as
Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the …

Abstract The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of
Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic …

Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

Highlights•More than 40 loci of interest have been associated with the risk of developing
AD.•Recent genetic data clearly implicate microglia as involved in the pathophysiological …

To provide better prevention and treatment, we need to understand the environmental and
genetic risks of Alzheimer's disease (AD). However, the definition of AD has been …

Development is a complex process regulated both by genetic and epigenetic and
environmental clues. Recently, long non-coding RNAs (lncRNAs) have emerged as key …